Singapore markets closed

VIVORYON THERAPEUTICS (05Y.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
Add to watchlist
0.52500.0000 (0.00%)
As of 03:22PM CET. Market open.
Full screen
Previous close0.5250
Open0.5150
Bid0.5280 x N/A
Ask0.5430 x N/A
Day's range0.5150 - 0.5250
52-week range0.5150 - 0.5250
Volume1,800
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Vivoryon Therapeutics N.V. Announces Changes to Board Composition

    Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced changes among the Non-Executive members of its Board of Directors. Professor Morten Asser Karsdal, MSc, PhD, mMBA and Ku

  • Simply Wall St.

    Here's Why Vivoryon Therapeutics (AMS:VVY) Must Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease

    Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease VIVIAD Phase 2b study did not meet its primary and key secondary endpointsVaroglutamstat was generally well tolerated with low discontinuation rates due to adverse events and no evidence of symptomatic ARIAs in the clinical settingVIVIAD is a comprehensive, diligently designed and high-quality study; baseline demographics in the study were highly representative of early AD patient p